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Introduction
Polychlorinated biphenyls (PCBs) are environmental pollutants that accumulate in the food chain due to their high lipophilicity and low biotransformation rate (Safe, 1993) . Their bioaccumulation has been detected in the environment (Olafsson et al., 1987; Kannan et al., 1989) and in human serum, adipose tissue, and milk (Safe et al., 1985; Dewailly et al., 1991; Fängström et al., 2002) .
A number of methylsulfonyl (MeSO 2 ) metabolites of PCBs have been found in several species of animals in Canada, Sweden, and East Greenland (Haraguchi et al., 1992; Bergman et al., 1994; Letcher et al., 1995; Chu et al., 2003; Sandala et al., 2004) and in both healthy humans and Yusho patients in Japan (Haraguchi et al., 1986 (Haraguchi et al., , 1989 .
Additionally, MeSO 2 -PCBs were identified in human milk, blood, liver and adipose tissue (Norén et al., 1996; Weistrand et al., 1997; Weistrand and Norén, 1997; Guvenius et al., 2002) . The main MeSO 2 -PCBs found are 3-and 4-MeSO 2 derivatives of non-planar PCBs (Haraguchi et al., 1992; Bergman et al., 1994; Letcher et al., 1995; Norén et al., 1996; Guvenius et al., 2002; Sandala et al., 2004) .
The 3-MeSO 2 -PCBs derived from non-planar PCBs, including 2,2',4,5,5'-pentachlorobiphenyl (PentaCB) 2,3',4',5-tetrachlorobiphenyl, and 2,2',3',4',5-pentachlorobiphenyl, show much greater activities for inducing hepatic drug-metabolizing enzymes than the corresponding parent PCBs (Kato et al., 1995 (Kato et al., , 1999b , while the 4-MeSO 2 -PCBs have no such capacity (Kato et al., 1995 There is a species-difference in the response to PCB-induced toxicities, including induction of drug-metabolizing enzymes, endocrine-disruption, carcinogenicity, and impairment of immune system (Safe, 1994) . As one of reasons for the species-difference, difference in a PCB metabolism would be considered.
In the present study, we examined a species-difference in the in vivo metabolism of 
Determination of PentaCB and its MeSO 2 metabolites. Amounts of PentaCB and
its MeSO 2 metabolites in the liver and feces were determined with gas chromatography as described previously (Bergman et al., 1992) . In the present study, the total area under the liver concentration versus time curve was calculated by the trapezoidal rule and shown as an AUC.
Statistics. The data obtained were statistically analyzed according to Student's t-test.
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Results
MeSO 2 metabolites of PentaCB. We have previously reported that when rats and mice were treated with PentaCB (34 µmol/kg), sum of hepatic 3-and 4-MeSO 2 metabolites detected in mice was two-fold higher than that in the rats (Haraguchi et al., 2005) . To further clarify a difference between rats and mice in the level of the MeSO 2 metabolites from PentaCB, we examined levels of the MeSO 2 metabolites in both the liver and feces from the PentaCB (342 µmol/kg)-treated rats and mice. Amounts of PentaCB and its MeSO 2 metabolites, 3-and 4-MeSO 2 -PentaCBs, after the PentaCB treatment in either the liver or the feces were clearly different between rats and mice.
Level of PentaCB in the liver of either rats or mice reached the maximum day 2 after the treatment and then decreased. The maximum levels in rats and mice were about 10 nmol/g tissue and about 35 nmol/g tissue, respectively. Levels of 3-and 4-MeSO 2 -PentaCBs in the mouse liver increased in a time-dependent fashion up to day 4 after the PentaCB treatment, and the maximum levels of 3-and 4-MeSO 2 -PentaCBs were about 4 nmol/g tissue and about 7 nmol/g tissue, respectively (Fig. 2) . On the other hand, in the rat liver, the 3-and 4-MeSO 2 metabolites were hardly produced, and levels of the metabolites were less than 1 nmol/g tissue at the any time examined.
AUC values in 3-and 4-MeSO 2 -PentaCBs in the liver were 17.50 and 31.54 nmol• day/g tissue, respectively, in mice and 2.92 and 4.83 nmol•day/g tissue, respectively, in rats. Thus, the AUC values obtained were much higher in mice than in rats.
In feces, level of PentaCB was higher in rats than in mice, whereas levels of 3-and 4-MeSO 2 metabolites of PentaCB were much higher in mice than in rats (Fig. 3) . In addition, the 3-MeSO 2 metabolite was hardly detected in the rat feces.
This article has not been copyedited and formatted. The final version may differ from this version. Serum thyroid hormone level. Effects of PentaCB on the levels of serum thyroid hormone T 4 in rats and mice were next examined. Levels of serum total T 4 in both rats and mice were significantly decreased by treatment with PentaCB (Fig. 4) . In either rats or mice, level of serum total T 4 decreased to 40-60% of the corresponding control level at day 1 after PentaCB treatment, and the decrease was maintained up to day 8 in each species of animal. In addition, no significant change in level of serum TSH after treatment with PentaCB was found in either rats or mice (data not shown).
Hepatic T 4 -UDP-GT activity.
We examined effects of PentaCB on hepatic T 4 -UDP-GT activity in rats and mice. Hepatic activities of T 4 -UDP-GT day 4 after treatment with PentaCB in rats and mice increased to 2-fold and 1.6-fold over the corresponding control levels, respectively (Table 1) .
Discussion
We have previously reported that there are species differences between rats and mice in the level of PentaCB and its metabolites, including methylsulfonylated and hydroxylated PentaCBs, and in their tissue distributions (Haraguchi et al., 2005) . In the present study, clear difference in the formation of MeSO 2 metabolites between the PentaCB-treated rats and mice was confirmed. A possible mechanism for the formation of the sulfur-containing metabolites from PentaCB is showed in Fig enzymes, especially CYP2B subfamily enzymes in rats, hamsters, and guinea pigs.
Considering a possible process of formation of MeSO 2 metabolites, difference between rats and mice in the amount of hepatic MeSO 2 metabolites formed from PentaCB would be attributed to the difference in the activity of CYP2B subfamily enzymes, glutathione S-transferase, and/or intestinal microflora C-S lyase.
We have previously reported that 3-MeSO 2 metabolite of PentaCB showed higher activity than a parent compound PentaCB for inducing hepatic drug-metabolizing "DMD #6189" 1 1 enzymes (Kato et al., 1995 (Kato et al., , 1999b and further demonstrated that some MeSO 2 metabolites, including 3-MeSO 2 -and 4-MeSO 2 -PentaCBs, could reduce serum total T 4 level in rats (Kato et al., 1998 (Kato et al., , 1999a (Kato et al., , 2000a . Accordingly, it has been expected that MeSO 2 -PentaCB metabolites contribute to decrease in the level of serum T 4 in PentaCB-treated animals. However, despite levels of MeSO 2 -PentaCB metabolites in both the liver and feces were much higher in mice than in rats, magnitudes of decrease in the level of serum total T 4 in rats and mice were almost the same. The present findings indicate that PentaCB-induced decrease in serum T 4 level is not dependent on only the MeSO 2 metabolites formed.
Decrease in the level of serum T 4 by PCB has been thought to occur through increase in hepatic T 4 -UDP-GT activity (Barter and Klaassen, 1994; Schuur et al., 1997; Van Birgelen et al., 1995) . However, it has been reported that difference between rats and mice in magnitude of decrease in level of serum total T 4 by 2,2',4,4',5,5'-hexachlorobiphenyl is not well correlated with that of increase in activity of T 4 -UDP-GT (Craft et al., 2002) . Likewise, we have reported that treatment with Kanechlor-500 resulted in a significant decrease in serum T 4 level in both rats and mice, although a significant increase in the activity of T 4 -UDP-GT enzymes, including UGT1A1 and UGT1A6, by the PCB occurred only in rats but not in mice (Kato et al., 2003) and further demonstrated that treatment with either Kanechlor-500 or PentaCB resulted in a drastic decrease in serum total T 4 level even in UGT1A1/1A6-deficient (Gunn) rats (Kato et al., 2004) . These previous reports strongly propose that the decrease in serum total T 4 level by PCBs including PentaCB does not occur only through increase in hepatic T 4 -UDP-GT activity, although significant increase in T 4 -UDP-GT activity by PentaCB was observed in both rats and mice (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. In the present study, level of serum TSH in either rats or mice was not significantly changed by PentaCB, indicating that TSH is not related to the PentaCB-induced decrease in serum T 4 level. In addition, it had been reported that serum TSH level was little affected by PCBs (Liu et al., 1995; Hood et al., 1999; Hallgren et al., 2001; Kato et al., 2003) .
In the PentaCB-treated rats and mice, 3-OH-, 3'-OH-, 4'-OH-and 3',4'-(OH) 2 -PentaCBs were found in the both liver and serum (Haraguchi et al., 2005) .
Mono-and di-hydroxylated PCB derivatives (Meerts et al., 2002; Lans et al., 1993) , Therefore, PentaCB-induced decrease in the level of serum total T 4 might occur, in part, through formation of the hydroxylated metabolites showing ability to bind to TTR.
In conclusion, we demonstrate herein that there is a remarked difference between rats and mice in the formation of MeSO 2 metabolites from PentaCB and further suggest that PentaCB-induced decrease in level of serum total T 4 is not necessarily dependent on the formation of the MeSO 2 metabolites. Additionally, the present findings demonstrate that PentaCB-induced decrease in serum total T 4 level in either rats or mice occurs without increase in serum TSH level. Although the PentaCB-induced decrease might occur, at least in part, through induction of T 4 -UDP-GT and/or formation of the hydroxylated metabolites from PentaCB, exact mechanism for PentaCB-induced decrease in serum thyroid hormones remains unclear.
Further studies on PentaCB-induced alterations of the level and function of T 4 -transporters in the liver and extrahepatic tissues would be necessary for understanding 
